Project: NEW THERANOSTIC NANOBODY FOR CMS4 COLORECTAL CANCER: SELECTIVE PET IMAGING AND TARGETED RADIOTHERAPY
| Acronym | ColoSelect (Reference Number: 114815) |
| Duration | 01/04/2021 - 01/04/2025 |
| Project Topic | We will deliver a first-in-class theranostic nanobody BOT1700, for use as PET imaging diagnostic and targeted radiotherapeutic, specific for consensus molecular subtype 4 (CMS4) colorectal cancer (CRC). BOT1700 specifically binds to the PDGF-beta receptor, which is overexpressed in the fibrotic stroma of CMS4-CRC patients. Preclinical proof-of-concept (PoC) as CMS4-specific PET imaging diagnostic will be obtained, in order to advance BOT1700 as targeted radiotherapy after the project. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 14 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Akademiska sjukhuset | Partner | Sweden |
| 2 | BiOrion Technologies B.V. | Coordinator | Netherlands |
| 3 | Immunitrack ApS | Partner | Denmark |
| 4 | Xenopat SL | Partner | Spain |